Alpha Cognition Inc. Common Stock (ACOG)

• Market cap: $78.8M
• 1 day: 4.74%
• 5 days: 12.42%
• 1 month: 9.09%
• 3 months: -8.00%
• 6 months: -3.16%
• Year to date: -2.65%
• 1 year: -3.16%
• 5 years: -3.16%
• 10 years: -3.16%
• Sector: Healthcare
• Industry: Biotechnology

About: Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Employees: 57

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

38.27% more ownership

Funds ownership: 0% [Q3] → 38.27% (+38.27%) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $20 262% upside
• Avg. target: $20 262% upside
• High target: $20 262% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Raghuram Selvaraju 38% 1-year accuracy 125 / 328 met price target

262% upside $20

Buy Reiterated

1 Apr 2025